Fang Qi and Danlei Wu of Fangda Partners highlight the main provisions in the recently introduced Fourth Amendment to the PRC Patent Law, which aims to establish a patent linkage system for patents in the pharmaceuticals industry, bring about significant changes to the design patent regime, strengthen patent protection against infringement and tackle the issue of abuse of patent rights
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
With the last changes to the Patent Law taking place in 2008, the 12-year gap between amendments runs longer than for other intellectual property statutes
This premium content is reserved for China Law & Practice Subscribers.
A Premium Subscription Provides:
A database of over 3,000 essential documents including key PRC legislation translated into English
A choice of newsletters to alert you to changes affecting your business including sector specific updates
Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment